Newborn Brain Assessment - CergenX Wave (NBT)

September 28, 2026 updated by: CergenX Limited

Determining Grade of Neonatal Encephalopathy - Agreement Between the Modified Sarnat Examination and Automated AI Assessment of Newborn Brain Function Using Wave Software

In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.

A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.

The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.

Study Overview

Study Type

Observational

Enrollment (Estimated)

165

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 months and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Infants at high-risk of Neonatal Encephalopathy

Description

Inclusion Criteria:

  1. Infants born at ≥36+0 weeks gestational age

  2. Informed consent obtained AND

  3. A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at < 1 hour of life) OR

  4. a) A pH of 7.01-7.15 or base deficit ≥ 16 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:

    • An APGAR score ≤5 at 10 minutes OR

    • Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR

    • An acute perinatal event:

      • Abnormal CTG (variable/late foetal HR decelerations)
      • Foetal bradycardia
      • Prolapsed/ruptured/tight nuchal cord
      • Shoulder dystocia
      • Uterine rupture
      • Maternal haemorrhage/placental abruption
      • Maternal trauma (e.g. vehicle accident)
      • Mother received CPR

Exclusion Criteria:

  1. Infants < 36 weeks gestation
  2. No parental/guardian consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Neonates

Neonates at risk of Neonatal Encephalopathy

The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.

Other Names:
  • eego amplifier

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Time Frame: From the enrolment and up to 6 hours after birth
From the enrolment and up to 6 hours after birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Time Frame: From enrolment of the participant and up to 30 hours after birth
From enrolment of the participant and up to 30 hours after birth
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Time Frame: From enrolment of the participant and up to 30 hours after birth
From enrolment of the participant and up to 30 hours after birth
Association between CergenX Wave software and clinical variables including discharge diagnosis
Time Frame: From enrolment of the participant and up to 30 hours after birth

Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses

From enrolment of the participant and up to 30 hours after birth
Assessment of healthcare professional (device users) satisfaction with usability of the device.
Time Frame: From enrolment of the participant and up to 30 hours after birth

An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale.

From enrolment of the participant and up to 30 hours after birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

September 10, 2026

First Submitted That Met QC Criteria

September 28, 2026

First Posted (Actual)

October 5, 2026

Study Record Updates

Last Update Posted (Actual)

October 5, 2026

Last Update Submitted That Met QC Criteria

September 28, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 25116
  • DT 2023 0435 (Other Grant/Funding Number: Department of Enterprise, Tourism and Employment. Enterprise Ireland)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe